2024-07-02 01:19:04 ET
Summary
- When excluding sales Pfizer generated due to COVID-19 vaccines and medication, the business is reporting solid growth.
- Especially the oncology business will drive growth in the years to come, and the Seagan acquisition might also contribute.
- With its high dividend yield and rather undervalued stock, PFE stock is a "Buy" at this point.
In the last few years, I covered several pharmaceutical companies - including Gilead Sciences, Inc. ( GILD ), Novo Nordisk A/S ( NVO ) or Eli Lilly and Company ( LLY ) - and wrote in one way or another about many different pharmaceutical companies. But one major pharmaceutical company I never wrote about is Pfizer Inc. ( PFE ). The company is one of the oldest and major pharmaceutical companies in the world and among the top 10 pharmaceutical companies (according to market capitalization )....
Read the full article on Seeking Alpha
For further details see:
Pfizer: It Could Be A Bargain